CVS nasal spray recall: Sinus relief product may cause deadly infection

CVS nasal spray recall: Sinus relief product may cause deadly infection
Health, Fitness & Food

A nasal spray sold under the CVS Health brand is being recalled because it may lead to life-threatening infections for certain patients, according to the Food and Drug Administration.

Product Quest Manufacturing, maker of the CVS Health 12 Hour Sinus Relief Nasal Mist, has issued a voluntary recall for the product after discovering what it called a “microbiological contamination.”

The Holly Hill, Florida-based maker of the clear, colorless liquid said it had not identified any incidents connected to the product, which was sold at many of CVS’ nearly 10,000 locations.

“Repetitive use of a nasal spray containing a gram-negative pathogen can potentially lead to colonization and subsequent infection which can be life threatening in certain patient populations, such as those with cystic fibrosis or immuno-compromised,” according to the recall statement.

The treatment, which comes in a 0.5-fluid-ounce white bottle inside an orange box, is used as a nasal decongestant.

The recall covers 16,896 packages with the UPC code 50428432365 and an expiration date of September 2019.

Product Quest urged customers to return the nasal spray to a CVS store or to discard it.

CVS representatives were not immediately available for comment Friday.

More from USA Today:

CVS to offer nationwide telemedicine service through smartphone video

You’ll soon be able to use your iPhone to pay for CVS prescriptions with Apple Pay

FDA expands recall of heart drug for possible cancer-causing contamination

Articles You May Like

Why Did CDC Sound the Alarm Over Eye Drops?
Financial coaching for parents in pediatric primary care reduces missed well-child care visit rates
Here’s How to End the U.S. Health Disadvantage
FDA Approves Leqembi (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer’s Disease
World Cancer Day 2023: Perspectives from The Institute of Cancer Therapeutics

Leave a Reply

Your email address will not be published. Required fields are marked *